We presume that several isoniazid PopPK studies exploring NAT2 genotype/single-nucleotide polymorphism (SNP) as a covariate would have been published to address the pharmacokinetic variabilities in isoniazid among different TB populations. This evidence concerns the gene NAT2 and tuberculosis.